Age-related changes of the immune system leading to hyporesponsiveness; a major player and predictor for biological behaviour of metastasized melanoma?
Completed
- Conditions
- metastasized melanomaskin cancer10040900
- Registration Number
- NL-OMON43667
- Lead Sponsor
- niversitair Medisch Centrum Groningen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 30
Inclusion Criteria
> 18 years of age
informed consent
metastasized melanoma
After treatment
Exclusion Criteria
severe anemia (Hb < 6.0)
concomitant chronic diseases that may affect immune system
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>To study the frequencies and differentiation status of CD4 and CD8 T cell<br /><br>populations (Tnaive, TCM, TEM, TEMRA) in young (18-50) and old (> 65) treatment<br /><br>naive metastasized melanoma patients at baseline and after treatment. In<br /><br>addition, the frequencies and differentiation of Treg in these two age groups<br /><br>will be assessed.</p><br>
- Secondary Outcome Measures
Name Time Method <p>To study the presence of markers of the immune risk phenotype in patients (e.g.<br /><br>CD4/CD8-ratio, CMV-status).<br /><br>To study markers of immune senescence (e.g. CD27, CD28) and exhaustion (e.g.<br /><br>PD1, CTLA-4).<br /><br>Furthermore, this study increases our understanding of the pathophysiology of<br /><br>behaviour and development of melanoma in elderly and young pateints.</p><br>